Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12901412 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2GLACHRM2CHRM1 | |
| SCHEMBL24700403 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2GLACHRM2CHRM1 | |
| SCHEMBL29334274 | 0.81 | GLA (0.41) | USP2SMN1; SMN2GLACHRM2CHRM1 | |
| SCHEMBL483259 | 0.80 | CHRM2 (0.43) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL20406585 | 0.80 | CHRM2 (0.43) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL28713624 | 0.80 | PTPN1 (0.38) | USP2SMN1; SMN2GLACHRM2CHRM1 | |
| SCHEMBL1274502 | 0.76 | RIPK1 (0.46) | — | |
| SCHEMBL8886176 | 0.76 | GLA (0.39) | USP2SMN1; SMN2GLACHRM2CHRM1 | |
| SCHEMBL5891823 | 0.76 | GLA (0.39) | USP2SMN1; SMN2GLACHRM2CHRM1 | |
| SCHEMBL23123431 | 0.76 | NAAA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431378-A | Ring-fused compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024160058-A1 | OXALIC ACID DIAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 四川科伦博泰生物医药股份有限公司 | 2024-08-08 | — | — | WO | disclosed |
| US-11447479-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2022-09-20 | — | — | US | disclosed |
| US-20210188828-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | US | disclosed |
| US-20210188828-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | US | disclosed |
| WO-2021124277-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188828-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885GLA 2051/4885 |
| US-11447479-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885GLA 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.